Growth hormonereleasing hormone (GHRH) peptides such as CJC-1295 and Tesamorelin are particularly popular because of their ability to naturally stimulate the bodys own production of growth hormone (GH), leading to higher levels of insulin-like growth factor-1 (IGF-1)
GLP1Ra, glucagon-like peptide 1 receptor agonists
GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the dual GIP/GLP-1 agonist tirzepatide carry the clinical evidence: STEP for semaglutide ( The New England Journal of Medicine , 2021), SURMOUNT for tirzepatide (NEJM, 2022), and SURMOUNT-OSA for tirzepatide in obstructive sleep apnea (NEJM, 2024)
You should not change your dosing regimen or stop taking tirzepatide as prescribed without discussing with your provider first
I., & Godfrey, M
Index to Diseases and Injuries References The following annotation back-references for this diagnosis code are found in the injuries and diseases index